Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has announced new preclinical results for its lead compound, Telomir-1. The study demonstrated that Telomir-1 restores mitochondrial function without inducing oxidative stress or cell proliferation in human cells derived from a patient with Hutchinson-Gilford Progeria Syndrome. Conducted in collaboration with Smart Assays Biotechnologies Ltd., the research used a Progeria human fibroblast cell line to assess Telomir-1's impact on mitochondrial energy production, oxidative balance, and cell replication. Key findings include increased mitochondrial energy production, reduced reactive oxygen species levels, and no increase in cell proliferation, with stronger activity observed in Progeria cells than in healthy fibroblasts. These results suggest potential relevance for diseases involving mitochondrial failure and oxidative stress, such as Parkinson's disease, ALS, Alzheimer's disease, Werner's syndrome, and Progeria. Telomir is completing IND-enabling studies for Telomir-1 and evaluating multiple clinical development paths.